T025
T025 is an orally active and highly potent inhibitor of Cdc2-like kinase (CLKs), with Kd values of 4.8, 0.096, 6.5, 0.61, 0.074, 1.5 and 32 nM for CLK1, CLK2, CLK3, CLK4, DYRK1A, DYRK1B and DYRK2, respectively. T025 induces caspase-3/7-mediated cell apoptosis. T025 reduces CLK-dependent phosphorylation. T025 exerts anti-proliferative activities in both hematological and solid cancer cell lines (IC50 values: 30-300 nM) . T025 has an anti-tumor efficiency, mainly for MYC-driven disease research[1].
Product Specifications
CAS Number
2407433-00-3
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
Apoptosis; CDK; DYRK
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/T025.html
Purity
99.64
Solubility
DMSO : 8.25 mg/mL (ultrasonic)
Smiles
CNC1=NC(NCC2=NC=CC=N2)=C(C(C3=CC=C(N=CC=C4)C4=C3)=CN5)C5=N1
Molecular Formula
C21H18N8
Molecular Weight
382.42
Precautions
H302, H315, H319
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CLK; DYRK1; DYRK2
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant N-Cadherin/CD325/CDH2 Monoclonal Antibody